NEWBURY, England--(BUSINESS WIRE)--Edwards Lifesciences announced new data from the COMMENCE aortic trial, demonstrating low rates of structural valve deterioration (SVD) in bioprosthetic aortic ...

Edwards Lifesciences Corp. received Food and Drug Administration approval for a new aortic heart valve, Inspiris Resilia. The valve expands on the device maker’s capability in tissue heart valves used ...

As it aims to broaden the reach of its replacement heart valves among younger patients, Edwards Lifesciences has put forward new clinical data showing its bioprosthetics can maintain their function ...

LONDON--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced one-year data highlighting the continued outstanding performance of its SAPIEN 3 Ultra RESILIA valve. The data were presented ...

CAIRO--(BUSINESS WIRE)-- Edwards Lifesciences (EW) today announced new eight-year data showing that patients receiving aortic surgical valves treated with its proprietary RESILIA tissue technology ...

IRVINE, Calif., March 31, 2022 /PRNewswire/ -- Edwards Lifesciences (NYSE: EW) today announced it received approval from the U.S. Food and Drug Administration (FDA) for the MITRIS RESILIA valve, a ...

It seems Wall Street has come to terms with the bread and butter of Edwards Lifesciences Corp.,as long as it’s profitable. For years, analysts called for Irvine-based Edwards to boost growth by moving ...

, the global leader in the science of heart valves and hemodynamic monitoring, today announced unprecedented long-term durability results for bovine pericardial heart valves, based on a study of the ...

CHICAGO (Reuters) - Edwards Lifesciences Corp said on Wednesday that it won U.S. regulatory approval for a device to replace diseased mitral valves, one of the most common forms of heart valve ...